Therapeutic Outlook in DLBCL: Evaluating Treatment Sequencing from Front-line to Relapsed Refractory Disease

Leading experts discuss the evolving treatment landscape in diffuse large B-cell lymphoma (DLBCL), focusing on front-line therapies, second-line immunotherapies, and strategies for managing relapsed/refractory cases."

EP. 1: Emerging Updates in Front-line Treatment Approach of DLBCL

January 3rd 2025

Matthew Matasar, MD and Nilajan Ghosh, MD, PhD, discuss first-line treatment strategies for DLBCL, including factors influencing treatment selection, unmet needs in first-line treatment options, the impact of the 2024 NCCN guideline updates, and practical guidance for community practitioners following insights from the POLARIX trial.

EP. 2: Insights from POLARIX: How do Novel Perspectives Influence Treatment Outcomes in DLBCL?

January 15th 2025

An expert discussion on evolving first-line treatment strategies for newly diagnosed diffuse large B-cell lymphoma (DLBCL), incorporating insights from the 2024 NCCN guidelines, unmet needs in 1L therapies, and the impact of POLARIX trial updates on the use of Pola+R-CHP in clinical practice.

EP. 3: The Evolving First-line Treatment Approach for DLBCL

January 15th 2025

An exploration of how first-line treatment practices for DLBCL have evolved with new options, emphasizing the role of relapsed/refractory disease risk in guiding treatment selection.

EP. 4: Future Considerations for Front-line Treatment of DLBCL

January 20th 2025

An overview of key studies and updates from ASH 2024 offering new insights into subsequent treatment strategies and safety management in the first-line setting for DLBCL.

EP. 5: Role of Testing in Treatment Decisions - ClonoSeq, PhaseSeq, MRD+Disease

January 20th 2025

A concise discussion of second-line treatment strategies for DLBCL, highlighting preferred regimens for transplant-eligible and ineligible patients, as well as treatment approaches based on the timing of relapse.

EP. 6: Second-line Treatment Landscape in Relapsed/Refractory DLBCL

January 27th 2025

A concise discussion of second-line treatment options for DLBCL, focusing on preferred regimens for transplant-eligible and ineligible patients, and tailored approaches based on relapse timing.

EP. 7: The Emerging Role of Second-line CAR T-cell Therapy in Relapsed/Refractory DLBCL

January 27th 2025

An analysis of key updates on CAR T-cell therapy in DLBCL from ZUMA-7 and TRANSFORM trials, exploring its potential as a primary second-line option, along with insights into efficacy and safety data for transplant-ineligible patients from ALYCANTE and PILOT studies

EP. 8: Safety Considerations for Second-line CAR T-cell Therapy in Relapsed/Refractory DLBCL

February 3rd 2025

A review of studies on safety management with CAR T-cell therapy, focusing on CRS/ICANS in the relapsed/refractory setting, key takeaways from Cohorts 4 and 6, and the impact of ZUMA-24 preliminary analysis on second-line safety strategies.

EP. 9: Real World Perspectives: Outcomes for CAR T-cell Therapy in Relapsed/Refractory DLBCL

February 3rd 2025

A review of real-world outcomes for CAR T-cell therapies in the relapsed/refractory setting from ASH 2024, comparing them to clinical trial results and addressing safety management concerns, toxicities, and prophylactic treatment options in practice.

EP. 10: Real World Perspectives: Considerations and Challenges for CAR T-cell Therapy in Relapsed/Refractory DLBCL

February 10th 2025

An overview of challenges with CAR T-cell therapy, including combating T-cell exhaustion, the pros and cons of outpatient administration, logistical barriers, and the role of polatuzumab in bridging therapy, along with a discussion of non-cellular second-line options such as pola+BR and findings from L-MIND compared to real-world data

EP. 11: Additional Perspectives Beyond CAR T-cell Regimens in Relapsed/Refractory DLBCL.: Bispecifics

February 10th 2025

A discussion of current trials on bispecific antibody therapies in DLBCL, highlighting key takeaways from STARGLO on Glofit+GemOx in relapsed/refractory disease, the potential role of bispecifics in second-line treatment, and the patient populations and care settings most likely to benefit from these emerging options.

EP. 12: Academic Insights for the Treatment of Later Relapsed/Refractory DLBCL

February 17th 2025

An overview of third-line treatment options for DLBCL, including choices for patients who did not receive CAR T-cell therapy or transplant in second-line, strategies for those who progress after CAR T-cell or transplant, and the impact of bispecific antibodies and ADCs, with insights from key studies on Glofit and Epcor in relapsed/refractory DLBCL and their implications for patient selection and care.

EP. 13: Bispecific Antibodies in the Relapsed/Refractory DLBCL Treatment Landscape

February 17th 2025

A discussion of major challenges in using bispecific antibodies in the relapsed/refractory DLBCL setting, focusing on dosing, safety concerns like CRS, and step-up dosing strategies, along with insights on best practices for community clinics; followed by a review of sequencing bispecific antibodies and CAR T-cell therapies in third-line treatment, informed by recent studies on bispecific/CAR T sequencing

EP. 14: Future Perspectives for the Treatment of Relapsed/Refractory DLBCL

February 24th 2025

A reflection on key accomplishments in DLBCL treatment, highlighting pivotal developments that have shaped clinical practice, followed by a look ahead to 2025, focusing on areas poised for significant progress and personal goals for the coming year